Last Updated : June 18, 2020
Details
Generic Name:
fluticasone furoate/vilanterol
Project Status:
Withdrawn
Therapeutic Area:
Asthma
Manufacturer:
GlaxoSmithKline Inc.
Call for patient/clinician input open:
Brand Name:
Breo Ellipta
Project Line:
Reimbursement Review
Project Number:
SR0568-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Breo Ellipta should be reimbursed preferentially to Advair to maximize asthma control in patients aged 18 years and older with reversible obstructive airways disease.
Submission Type:
Resubmission
Fee Schedule:
Schedule B
Indications:
Asthma
Date NOC Issued:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient input posted | April 04, 2018 |
| Patient group input closed | May 24, 2018 |
| Clarification: - No patient input submission received | |
| Submission received | May 02, 2018 |
| Submission accepted | May 16, 2018 |
| Review initiated | May 17, 2018 |
| Draft CADTH review report(s) sent to sponsor | August 01, 2018 |
| Comments from sponsor on draft CADTH review report(s) received | August 13, 2018 |
| Redaction requests from sponsor on draft CADTH review report(s) received | August 15, 2018 |
| Clarification: - Voluntarily withdrawn by the manufacturer on 2018-08-14 | |
Last Updated : June 18, 2020